Novogen's CEO says one of the Australian company's drugs has shown promise in pretrial as a way to kill cancer stem cells.
India's top drugmaker, Sun Pharmaceutical Industries, has agreed to buy GlaxoSmithKline's opiates business in Australia, placing it as one of three owners that control the crop and production in Tasmania that is the world's largest legal supplier of pharmaceutical-grade opiates for painkillers.
Australia's Senate has passed two-year-old legislation that would afford drugmakers a bit of compulsory licensing and allow them to share patent application reviews and approvals with New Zealand, the decision of one being the decision of the other.
Bangladesh's pharmaceuticals industry has become a $1.5 billion business producing 97% of the nation's consumption, but it has a long way to go in various segments including exports, according to Shawkat Haider, general manager of Beximco Pharmaceuticals.
Australia's PhytoTech Medical last week became the country's first medical marijuana company to first be listed on the country's Australian Securities Exchange, where it raised AUS $5.9 million ($4.7 million) in support of its single-use vaporizer to administer medical marijuana at a precise dosage.
SINGAPORE-- Australia's Therapeutic Goods Administration (TGA) has updated guidance on the release of medicine products from the last manufacturer in the supply chain responsible for certifying the quality before the products are released onto the Australian market.
Researchers at Curtin University's Biotechnology and Drug Development Research Laboratory in Perth, Australia, are developing a microcapsule formulation that they say improves the drug delivery and absorption of diabetes drugs.
Hospira is recalling another product manufactured at a plant in Australia which last year received an FDA warning letter. The Lake Forest, IL-based company is voluntarily recalling 3,306 vials of the cancer drug dacarbazine because of discoloration, according to the most recent FDA Enforcement Report.
The biosimilars market has attracted some big companies with even bigger claims about their ability to drive down manufacturing costs, with Samsung and its ambition to undercut biologic prices by 50% the standout example. Now a small Australian biotech is trumpeting the cost-saving it can realize after marrying its expression technology to the scale of the Serum Institute of India.
Australian survivors of the deadly meningococcal B strain are mounting pressure on the country's Pharmaceutical Benefits Advisory Committee to include Novartis' Bexsero, the only approved vaccine for the disease, on its national immunization plan when it meets next month.